Moderna, Inc. (MRNA) shares fell 4.9% to $255.75 as of November 10, 2026, a moderate decline from the prior close of $269.00. BestStocks flagged the session as a major change for MRNA. Below, we break down what changed for MRNA, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
MRNA fell 4.9% to $255.75
Despite strong Q3 earnings with better-than-expected revenue and a raised 2026 guidance, alongside progress on its first cancer therapy (intismeran targeting year-end 2026 FDA filing), MRNA is down 5.20% intraday to $255.00. The decline suggests investors are discounting the near-term outlook despite the positive results, possibly reflecting concerns about the company's heavy dependence on COVID-related revenue as noted by Motley Fool; volume is tracking at 0.91x the time-adjusted average, indicating normal participation. Moderna's year-end 2026 FDA filing for intismeran (personalized cancer therapy) and Q4 2026 results (earnings scheduled February 12, 2027) for evidence of guidance track and oncology traction.
This summary describes the catalyst and move as first detected on Nov 10, 2026, 11:42 AM EST; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
For Moderna, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Earnings beat — stock sold off (sell-the-news reaction); Positive price momentum. Weighing against that: Negative session, down 4.9%; Moderna fell 6.15% to $242.50, extending recent weakness ahead of earnings scheduled for November 6, 2026. Wall Street's consensus price target sits at $140.20, implying -45.2% downside from $255.75. Over the past 90 days analysts logged 3 upgrades and 3 downgrades. BestStocks rates the overall signal quality low (53/100). With earnings roughly 94 days out, the next report is the most likely near-term test of the move.
MRNA price reaction
MRNA last traded at $255.75, down $13.25 (-4.93%) from the previous close of $269.00. The session traded on 0.4× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $198.85 and $269.00, and it currently sits about 81% of the way up that band.
Bullish and bearish analyst opinions on Moderna, Inc. (MRNA)
▼Latest catalyst·strengthens the bear case
The latest catalyst — a materially negative development — it strengthens the bear case, in line with the prevailing bearish analyst lean.
The consensus analyst price target on Moderna, Inc. (MRNA) is $140.20, 45.2% below the recent $255.75. Over the past 90 days analysts logged 3 upgrades, 11 maintains, and 3 downgrades. Here is how the bullish and bearish cases on MRNA line up.
▲ The bullish case
+The Street's most bullish target is $305.00 (+19.3%).
+3 analyst upgrades in the past 90 days, most recently Argus Research to Buy (2026-08-28).
+Earnings beat — stock sold off (sell-the-news reaction).
+Positive price momentum.
▼ The bearish case
−The consensus analyst price target of $140.20 sits 45.2% below the recent $255.75, so the average target sees limited room to run.
−The most bearish analyst target is $25.00 (-90.2%).
−3 analyst downgrades in the past 90 days, most recently William Blair to Market Perform (2026-10-27).
−Negative session, down 4.9%.
−Moderna fell 6.15% to $242.50, extending recent weakness ahead of earnings scheduled for November 6, 2026.
Bull vs bear balanceBearish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 10, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Moderna surged 9.2% to $277.58 after Piper Sandler raised its price target to $305 per share, citing blockbuster potential for the melanoma vaccine candidate intismeran in combination with Merck's Keytruda. The move builds on momentum from Moderna's late-October Q3 results, which included a surprise profit, $1.31 billion revenue (up 29% year-over-year), and a raised full-year 2026 revenue outlook to 15–25% growth from a prior 10% ceiling, per Zacks earnings call highlights and Yahoo Finance.
Material / Earnings2026-11-06+5.3%
Moderna, Inc. (MRNA) reported EPS of $0.38 vs. consensus estimate of −$1.10 for Q3 FY2026, beating expectations by 134.5%.
Moderna reported Q3 earnings that beat estimates with a surprise $162 million net profit (38¢/share) on $1.3B revenue, and raised full-year 2026 guidance to 15–25% revenue growth, according to The Wall Street Journal and Zacks. The stock gained 5.66% to $255.12 on the results, driven by strong overseas vaccine demand and momentum from its Merck-partnered melanoma cancer vaccine program.
Moderna fell 6.15% to $242.50, extending recent weakness ahead of earnings scheduled for November 6, 2026. Seeking Alpha's earnings preview acknowledges a melanoma vaccine breakthrough but argues the stock is overvalued at current levels, citing a $221 fair-value estimate. Volume of 3.99 million shares (1.06x expected ratio) is normal for 80 minutes into the session.
Moderna rose 6.26% to $234.65, gaining ground ahead of earnings scheduled for November 5. The Motley Fool published a bullish piece questioning whether the stock could double, while Bank Julius Baer sold a position; volume of 3.6M shares ran at 0.93x the time-adjusted average, indicating normal trading activity. The move may reflect positioning ahead of the earnings call, where consensus expects a loss of $1.10 per share.
Moderna shares plunged 19.58% to $197.67 after cancer-vaccine trial data leaked ahead of its scheduled presentation at ESMO 2026, per Barron's. The company and partner Merck had announced positive Phase 3 results for intismeran autogene plus KEYTRUDA in melanoma, but premature circulation of the data sparked the sharp sell-off. Volume surged to 42.8M shares—2.48x the historical average for this time of day—and a securities fraud investigation was announced the same day.
Moderna rose 4.58% to $237.28, extending recent momentum. The evidence includes a prior report (Oct 30, 2025) of potential buyout talks via STAT News that drove a 12% surge, and a Barclays analyst upgrade (Aug 25, 2026) that raised the price target to $125 from $48 while maintaining Equal Weight. Current intraday volume of 8.1M shares is 0.91x historical average—normal for this point in the session.
Moderna shares fell 10.49% to $211.69 on October 16, 2026, driven by pre-event profit-taking and derisking ahead of a Phase 3 data presentation later in the month for its personalized melanoma vaccine partnership with Merck, according to investing.com. The decline follows a multi-week rally that pushed the stock near 52-week highs, prompting investors to lock in gains; sentiment was also pressured by insider selling (Form 144 filings from executives including Stephen Hoge) and news that rival Summit Therapeutics hired two former Moderna cancer vaccine scientists.
In-depth MRNA event analyses
Permanent, dated analyses of MRNA's most significant sessions.
MRNA fell 4.9% to $255.75. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did MRNA stock fall?
MRNA lost 4.93% ($13.25) versus the prior close of $269.00, last trading at $255.75 on 0.4× average volume.
When is Moderna, Inc.'s next earnings date?
MRNA's next earnings report is estimated for 2027-02-12 — about 94 days away.
What is the analyst price target for MRNA?
The consensus analyst price target for MRNA is $140.20, about 45.2% below the current $255.75. Over the past 90 days, analysts recorded 3 upgrades, 11 maintains, and 3 downgrades.
How BestStocks tracks MRNA
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MRNA-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for MRNA, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 10, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
